Non-alcoholic steatohepatitis - from NAFLD to MAFLD;Nicht-alkoholische steatohepatitis - von NAFLD zu MAFLD

Therapeutische Umschau

Volumn 68, Issue 4, 2011, Pages 183-188

  Balmer, Maria Luisa ^a   Dufour, Jean François ^a  

^a UNIVERSITY OF BERN   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TOCOPHEROL; INSULIN SENSITIZING AGENT; LIVER ENZYME; URSODEOXYCHOLIC ACID;

ALCOHOLIC FATTY LIVER; ANTIOXIDANT ACTIVITY; ARTICLE; DIABETES MELLITUS; DISEASE ACTIVITY; DISEASE ASSOCIATION; DISEASE SEVERITY; FATTY LIVER; HEPATITIS; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; INSULIN SENSITIVITY; LIFESTYLE MODIFICATION; LIVER BIOPSY; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER FIBROSIS; LIVER FUNCTION TEST; LIVER HISTOLOGY; METABOLIC SYNDROME ASSOCIATED FATTY LIVER DISEASE; METABOLIC SYNDROME X; NONALCOHOLIC FATTY LIVER; OBESITY; PATHOPHYSIOLOGY; RISK FACTOR;

BIOPSY; CARCINOMA, HEPATOCELLULAR; CAUSALITY; CROSS-SECTIONAL STUDIES; DIAGNOSIS, DIFFERENTIAL; DISEASE PROGRESSION; FATTY LIVER; FATTY LIVER, ALCOHOLIC; HUMANS; LIVER; LIVER CIRRHOSIS; METABOLIC SYNDROME X;

EID: 79953294775     PISSN: 00405930     EISSN: None     Source Type: Journal    
DOI: 10.1024/0040-5930/a000148     Document Type: Article

References (13)

1. Stickel F LF. NASH, Insulinre-sistenz und Diabetes mellitus. Med Welt. 2007; 58; 231-9.
2. Bellentani S, Saccoccio G, Masutti F, Croce LS, Brandi G, Sasso F, et al. Prevalence of and risk factors for hepatic steatosis in Northern Italy. Ann Intern Med. 2000; 132; 112-7.
3. Paradis V, Zalinski S, Chelbi E, Guedj N, Degos F, Vilgrain V, et al. Hepatocellular carcinomas in pa-tients with metabolic syndrome often develop without significant liver fibrosis: a pathological analysis. Hepatology. 2009; 49; 851-9.
4. Day C P, James OF. Steatohepatitis: a tale of two «hits»? Gastroenterolo-gy. 1998; 114; 842-5.
5. Rotman Y, Koh C, Zmuda JM, Kleiner DE, Liang TJ. The association of genetic variability in pa-tatin-like phospholipase domain-containing protein 3 (PNPLA3) with histological severity of nonalcoholic fatty liver disease. Hepatol-ogy. 2010; 52; 894-903.
6. Foucher J, Chanteloup E, Vergniol J, Castera L, Le Bail B, Adhoute X, et al. Diagnosis of cirrhosis by transient elastography (FibroScan): a prospective study. Gut. 2006; 55; 403-8.
7. Kleiner DE, Brunt EM, Van Natta M, Behling C, Contos MJ, Cum-mings OW, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology. 2005; 41; 1313-21.
8. Sanyal AJ, Chalasani N, Kowdley K V, McCullough A, Diehl AM, Bass NM, et al. Pioglitazone, Vitamin E, or Placebo for Nonalcoholic Steato-hepatitis. N Engl J Med. 2010; 362; 1675-85.
9. Ratziu V, Giral P, Jacqueminet S, Charlotte F, Hartemann-Heurtier A, Serfaty L, et al. Rosiglitazone for nonalcoholic steatohepatitis: one-year results of the randomized placebo-controlled Fatty Liver Improvement with Rosiglitazone Therapy (FLIRT) Trial. Gastroen-terology. 2008; 135; 100-10.
10. Dufour JF, Oneta CM, Gonvers JJ, Bihl F, Cerny A, Cereda JM, et al. Randomized placebo-controlled trial of ursodeoxycholic acid with vitamin e in nonalcoholic steato-hepatitis. Clin Gastroenterol Hepa-tol. 2006; 4; 1537-43.
11. Balmer ML, Siegrist K, Zimmer-mann A, Dufour JF. Effects of urso-deoxycholic acid in combination with vitamin E on adipokines and apoptosis in patients with nonalcoholic steatohepatitis. Liver Int. 2009; 29; 1184-8.
12. Lewis JR, Mohanty SR. Nonalcoholic fatty liver disease: a review and update. Dig Dis Sci. 2010; 55; 560-78.
13. Ratziu V, Bellentani S, Cortez-Pinto H, Day C, Marchesini G. A position statement on NAFLD/NASH based on the EASL 2009 special conference. J Hepatol. 2010; 53; 372-84.